{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T23:30:24Z","timestamp":1694561424456},"reference-count":43,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2010,7,19]],"date-time":"2010-07-19T00:00:00Z","timestamp":1279497600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epidemiol. Infect."],"published-print":{"date-parts":[[2011,5]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>The 7-valent pneumococcal conjugate vaccine (PCV7) was included in the routine infant immunization schedule in Ireland in September 2008. We determined the serotype of 977 <jats:italic>S. pneumoniae<\/jats:italic> isolates causing invasive disease between 2000\u20132002 and 2007\u20132008, assessed for the presence of the recently described serotype 6C and determined the susceptibility of isolates during 2007\u20132008 to penicillin and cefotaxime. Serotype 14 was the most common serotype during both periods and 7\u00b77% of isolates previously typed as serotype 6A were serotype 6C. During 2000\u20132002 and 2007\u20132008, PCV7 could potentially have prevented 85% and 74% of invasive pneumococcal disease in the target population (i.e. children aged &lt;2 years), respectively. The level of penicillin non-susceptibility was 17% in 2007\u20132008. Ongoing surveillance of serotypes is required to determine the impact of PCV7 in the Irish population and to assess the potential of new vaccines with expanded valency.<\/jats:p>","DOI":"10.1017\/s0950268810001743","type":"journal-article","created":{"date-parts":[[2010,7,19]],"date-time":"2010-07-19T13:10:43Z","timestamp":1279545043000},"page":"783-790","source":"Crossref","is-referenced-by-count":9,"title":["Serotype distribution of <i>Streptococcus pneumoniae<\/i> causing invasive disease in the Republic of Ireland"],"prefix":"10.1017","volume":"139","author":[{"given":"I.","family":"VICKERS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"FITZGERALD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"MURCHAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"COTTER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"O'FLANAGAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"CAFFERKEY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"HUMPHREYS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2010,7,19]]},"reference":[{"key":"S0950268810001743_ref009","doi-asserted-by":"publisher","DOI":"10.1128\/9781555815820.ch10"},{"key":"S0950268810001743_ref004","doi-asserted-by":"publisher","DOI":"10.1086\/606118"},{"key":"S0950268810001743_ref016","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.011"},{"key":"S0950268810001743_ref011","doi-asserted-by":"publisher","DOI":"10.1086\/527396"},{"key":"S0950268810001743_ref021","unstructured":"21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Wayne, PA, USA: CLSI, 2008."},{"key":"S0950268810001743_ref017","doi-asserted-by":"publisher","DOI":"10.1086\/500941"},{"key":"S0950268810001743_ref034","doi-asserted-by":"publisher","DOI":"10.1086\/597044"},{"key":"S0950268810001743_ref031","doi-asserted-by":"publisher","DOI":"10.1086\/528996"},{"key":"S0950268810001743_ref020","doi-asserted-by":"publisher","DOI":"10.1128\/JB.186.24.8181-8192.2004"},{"key":"S0950268810001743_ref026","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268807009715"},{"key":"S0950268810001743_ref022","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2004.00894.x"},{"key":"S0950268810001743_ref038","doi-asserted-by":"publisher","DOI":"10.3201\/eid1601.090650"},{"key":"S0950268810001743_ref039","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01984-08"},{"key":"S0950268810001743_ref033","doi-asserted-by":"publisher","DOI":"10.3201\/eid1402.070807"},{"key":"S0950268810001743_ref025","doi-asserted-by":"publisher","DOI":"10.1086\/317924"},{"key":"S0950268810001743_ref029","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2005.04.006"},{"key":"S0950268810001743_ref007","unstructured":"7. European Centre for Disease Prevention and Control (ECDC). Use of pneumococcal polysaccharide vaccine for subjects over 65 years of age during an inter-pandemic period. Technical report of the scientific panel on vaccines and immunisation, Stockholm, Sweden, 2007, pp. 1\u201319."},{"key":"S0950268810001743_ref035","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2007.11.026"},{"key":"S0950268810001743_ref010","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199506000-00007"},{"key":"S0950268810001743_ref037","article-title":"Prevalence and molecular characterization of Streptococcus pneumoniae serotype 6C causing invasive disease in Gipuzkoa, northern Spain, 1990\u20132009","author":"Marimon","journal-title":"European Journal of Clinical Microbiology and Infectious Diseases"},{"key":"S0950268810001743_ref024","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.8.3641-3648.2003"},{"key":"S0950268810001743_ref018","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(89)80068-4"},{"key":"S0950268810001743_ref041","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01454-08"},{"key":"S0950268810001743_ref001","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.6.973"},{"key":"S0950268810001743_ref002","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(05)70083-9"},{"key":"S0950268810001743_ref003","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02199-06"},{"key":"S0950268810001743_ref005","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.47549-0"},{"key":"S0950268810001743_ref023","doi-asserted-by":"publisher","DOI":"10.1086\/423820"},{"key":"S0950268810001743_ref006","doi-asserted-by":"publisher","DOI":"10.1086\/431524"},{"key":"S0950268810001743_ref008","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.16.2043"},{"key":"S0950268810001743_ref012","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e318124a494"},{"key":"S0950268810001743_ref013","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022823"},{"key":"S0950268810001743_ref014","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe068038"},{"key":"S0950268810001743_ref015","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.6.1271"},{"key":"S0950268810001743_ref019","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00510-07"},{"key":"S0950268810001743_ref027","doi-asserted-by":"publisher","DOI":"10.1080\/00365540500532852"},{"key":"S0950268810001743_ref028","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2008.02.004"},{"key":"S0950268810001743_ref030","doi-asserted-by":"publisher","DOI":"10.1086\/374624"},{"key":"S0950268810001743_ref032","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00310-08"},{"key":"S0950268810001743_ref036","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.01919-08"},{"key":"S0950268810001743_ref040","doi-asserted-by":"publisher","DOI":"10.1086\/313608"},{"key":"S0950268810001743_ref042","first-page":"378","article-title":"Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults","volume":"66","author":"Hak","year":"2008","journal-title":"Netherlands Journal of Medicine"},{"key":"S0950268810001743_ref043","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)04237-9"}],"container-title":["Epidemiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0950268810001743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,27]],"date-time":"2019-04-27T08:43:45Z","timestamp":1556354625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0950268810001743\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,19]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0950268810001743"],"URL":"https:\/\/doi.org\/10.1017\/s0950268810001743","relation":{},"ISSN":["0950-2688","1469-4409"],"issn-type":[{"value":"0950-2688","type":"print"},{"value":"1469-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,19]]}}}